Press Release | NeoGenomics Laboratories

January 11, 2022

NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

December 13, 2021

NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary

December 10, 2021

NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers

November 30, 2021

NeoGenomics To Participate In The Stephens Annual Investment Conference 2021

November 10, 2021

NeoGenomics Appoints Dave Daly to Its Board of Directors

November 4, 2021

NeoGenomics Announces Leadership Team Transition

November 4, 2021

NeoGenomics Reports Revenue of $121 Million in the Third Quarter

October 19, 2021

NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients